A novel autologous bone graft substitute comprised of rhBMP6 blood coagulum as carrier tested in a randomized and controlled Phase I trial in patients with distal radial fractures.

Autor: Durdevic D; Clinical Hospital Center 'Sisters of Mercy', Clinic of Traumatology, Draskoviceva 19, 10000 Zagreb, Croatia., Vlahovic T; Clinical Hospital Center 'Sisters of Mercy', Clinic of Traumatology, Draskoviceva 19, 10000 Zagreb, Croatia., Pehar S; Laboratory for Mineralized Tissues, Centre for Translational and Clinical Research, University of Zagreb School of Medicine, Salata 11, 10000 Zagreb, Croatia., Miklic D; Clinical Hospital Center 'Sisters of Mercy', Clinic of Traumatology, Draskoviceva 19, 10000 Zagreb, Croatia., Oppermann H; Genera Research, Svetonedeljska 2, Kalinovica, 10436, Rakov Potok, Croatia., Bordukalo-Niksic T; Laboratory for Mineralized Tissues, Centre for Translational and Clinical Research, University of Zagreb School of Medicine, Salata 11, 10000 Zagreb, Croatia., Gavrankapetanovic I; University Clinical Center Sarajevo, Clinic of Orthopedics and Traumatology, Bolnicka 25, 71000 Sarajevo, Bosnia and Herzegovina., Jamakosmanovic M; University Clinical Center Sarajevo, Clinic of Orthopedics and Traumatology, Bolnicka 25, 71000 Sarajevo, Bosnia and Herzegovina., Milosevic M; School of Public Health 'Andrija Stampar', University of Zagreb School of Medicine, Rockefellerova 4, 10000 Zagreb, Croatia., Martinovic S; SmartMedico, Zupanova 5, 10000 Zagreb, Croatia., Sampath TK; perFormBiologics Inc., Holliston, MA 01746, USA., Peric M; Department for Intracellular Communication, Centre for Translational and Clinical Research, University of Zagreb School of Medicine, Salata 2, 10000 Zagreb, Croatia., Grgurevic L; Laboratory for Mineralized Tissues, Centre for Translational and Clinical Research, University of Zagreb School of Medicine, Salata 11, 10000 Zagreb, Croatia., Vukicevic S; Laboratory for Mineralized Tissues, Centre for Translational and Clinical Research, University of Zagreb School of Medicine, Salata 11, 10000 Zagreb, Croatia. Electronic address: slobodan.vukicevic@mef.hr.
Jazyk: angličtina
Zdroj: Bone [Bone] 2020 Nov; Vol. 140, pp. 115551. Date of Electronic Publication: 2020 Jul 27.
DOI: 10.1016/j.bone.2020.115551
Abstrakt: Bone morphogenetic proteins (BMPs) are known to induce new bone formation in vivo but treating trabecular bone defects with a BMP based therapeutic remains controversial. Here, we evaluated the safety and efficacy of a novel Autologous Bone Graft Substitute (ABGS) comprised of recombinant human BMP6 (rhBMP6) dispersed within an autologous blood coagulum (ABC) as a physiological natural carrier in patients with a closed distal radial fracture (DRF). We enrolled 32 patients in a randomized, standard of care (SoC) and placebo (PBO) controlled, double-blinded Phase I First in Human (FiH) clinical trial. ABGS was prepared from peripheral blood as 250 μg rhBMP6/mL ABC or PBO (1 mL ABC containing excipients only) and was administered dorsally via a syringe injection into the fracture site following closed fracture fixation with 3 Kirschner wires. Patients carried an immobilization for 5 weeks and were followed-up for 0 to 26 weeks by clinical examination, safety, serial radiographic analyses and CT. During the 13 weeks follow-up and at 26 weeks post study there were no serious adverse reactions recorded. The results showed that there were no detectable anti-rhBMP6 antibodies in the blood of any of the 32 patients at 13- and 26-weeks following treatment. Pharmacokinetic analyses of plasma from patients treated with ABGS showed no detectable rhBMP6 at any time point within the first 24 h following administration. The CT image and radiographic analyses score from patients treated with AGBS showed significantly accelerated bone healing as compared to PBO and SoC at 5 and 9 weeks (with high effect sizes and P = 0.027), while at week 13 all patients had similar healing outcomes. In conclusion, we show that intraosseous administration of ABGS (250 μg rhBMP6/mL ABC) into the distal radial fracture site demonstrated a good tolerability with no serious adverse reactions as well as early accelerated trabecular bone healing as compared to control PBO and SoC patients.
Competing Interests: Declaration of competing interest LG, HO and SV have an issued patent US8197840 and licensed to Genera Research (GR). HO is an employee of Genera Research. TKS received grants and other from perForm Biologics during the study. MP, SM, LG, TBN, SV and HO collaborate on the development of a new drug for bone repair under the consortium of partners funded by EU HORIZON2020 (GA No 779340 [OSTEOproSPINE]). Other authors declare no conflict of interest.
(Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: